Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press ReleaseSee all News
Ann F. HanhamManaging Director, Canada
Ann F. Hanham joined Burrill & Company in February, 2000, and has utilized her background in clinical and regulatory affairs to lead deals in diagnostic, device and therapeutic opportunities. Prior to joining Burrill & Company, Ann was a co-founder and Vice President of Clinical & Regulatory Affairs at InterMune Pharmaceuticals, and prior to that, the Senior Director for Oncology Product Development at Otsuka Pharmaceuticals and the Medical Director for Celtrix Pharmaceuticals. She has also worked for Becton Dickinson in both regulatory and clinical affairs in their monoclonal antibody program, and as a regulatory toxicologist with the Health Protection Branch of Health and Welfare Canada. Dr. Hanham holds a Ph.D. from the University of British Columbia, an M.Sc. from Simon Fraser University, and a B.Sc. from the University of Toronto. She was also Board Certified in Toxicology in 1986. She is currently the CEO of Adlyfe, and a member of the Board of Directors of Adlyfe, Aerovance, Cardiokine (observer), Endocyte, Logical Therapeutics (observer), SCYNEXIS, Taiwan Liposome Company, and Waterstone. Ann is also a charter member of the C100, a group dedicated to assisting Canadian entrepreneurs.